International researchers confirm potential inhibitors to combat glioblastoma

After diagnosis, only thirty percent of glioblastoma (an aggressive brain cancer) patients have survived more than two years. However, San Diego Supercomputer Center (SDSC) Research Scientist Igor Tsigelny recently collaborated with colleagues from Sweden's Karolinska Institute and the Pasteur Institute in France to improve the prognosis of those struck with this typically fatal cancer.

The paper, 'A New Strategy for Designing Allosteric Modulators of Transcription Factor Dimerization' was published this month in the Proceedings of the National Academy of Sciences and experimentally confirms researchers' earlier findings on using interface inhibitors to combat glioblastoma, said Tsigelny.

Tsigelny, who specializes in personalized cancer medicine and computational drug design, previously worked on these interface inhibitors and their role in brain cancer treatment, specifically focused on OLIG2 (oligodendrocyte transcription factor 2), which is primarily known for its relationship with cancers such as glioblastoma and leukemia.

In past studies, the development of OLIG2 inhibitors has been challenging because of the lack of specific pockets and extensive protein-to-protein interfaces. Now, though, we have worked with our colleagues at Karolinska and Pasteur, Lars Terenius and Jean-Pier-Changeux, to make significant progress with the latest experiments."

Igor Tsigelny, SDSC Research Scientist

Sho Oasa, Vladana Vukojević and Rudolf Rigler from Karolinska Institute also participated in this study.

Specifically, the researchers completed a direct molecules-interaction study that demonstrated how inhibitors can deter the OLIG2 heterodimer interface in glioblastoma cells. The team took a closer look at the molecular interactions by using Fluorescence Cross-Correlation Spectroscopy (FCCS), which was developed in the mid-1990s. An extension of FCS (fluorescence correlation spectroscopy), FCCS allowed the scientists to measure two species simultaneously (by co-incidence). Labeled with two different colored fluorescent probes, the cross-correlation analysis in the cells confirmed the potential of using OLIG2 inhibitors for treatment.